Before you continue with your order please take a moment to carefully review the following information below.

 

Human-based glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Semaglutide (compounded), Adlyxin®, Byetta®, Bydureon®, Ozempic®, Rybelsus®, Trulicity®, Victoza®, Wegovy®, and Mounjaro®, are prescribed alongside a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) outside a healthy range.

​

Dietary Recommendations While Using GLP-1 RAs:

​

• Eat a high-fiber diet: Focus on fruits and vegetables rich in fiber.

• Consume small, high-protein meals: Digestion may slow down on this medication.

• Avoid high-fat foods: They take longer to digest.

• Stay hydrated: Drink at least 32 oz of water daily to prevent constipation.

​

Do Not Take This Medication If:

​

• You have a personal or family history of medullary thyroid carcinoma (Thyroid Cancer).

• You have a personal history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

• You are pregnant or plan to become pregnant while taking this medicine.

• You have diabetes and/or are taking any medications to lower blood sugar levels without consulting your endocrinologist or primary care provider. Especially avoid using insulin concurrently as it may increase the risk of hypoglycemia (low blood sugar), necessitating dosage adjustments.

• You are allergic to Semaglutide or any other GLP-1 agonist such as Adlyxin®, Byetta®, Bydureon®, Ozempic®, Rybelsus®, Trulicity®, Victoza®, Wegovy®, or Mounjaro® (this list is not all-inclusive).

​

Possible Drug Interactions:

​

• Anti-diabetic agents: Particularly insulin and sulfonylureas (e.g., glyburide, glipizide, glimepiride, tolbutamide) due to the increased risk of hypoglycemia. Do not use other GLP-1 agonists concurrently.

• Blood pressure medications: Monitor your blood pressure at home as weight loss on this medication might necessitate adjusting your blood pressure medication dosage. Maintain a blood pressure diary.

​

Possible Side Effects:

​

• Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia, flatulence, gastroenteritis, and gastroesophageal reflux disease.

• Subcutaneous injections may cause itching, burning at the site of administration, and skin thickening.

​

Emergency and Reporting:

​

• Contact your healthcare provider if you notice side effects not listed above. Seek immediate medical help for serious allergic reactions (e.g., rash, itching/swelling of face/tongue/throat, severe dizziness, trouble breathing).

• Report adverse side effects to your clinician. In an emergency, call 911 immediately.

​

Semaglutide Protocol:

​

• Monthly Refills: Request a refill every 30 days and self-report your current weight, blood pressure, treatment concerns, changes in prescribed medications, medical history, and desired weight loss outcome.

• Refill Method: Use our mobile number for the most efficient refill requests. Allow 7-10 business days for some forms of semaglutide. Report promptly to avoid delays.

• In-office Visits: Assistance is available. Notify our office of any concerns or questions.

​

Consent and Agreement:

​

By continuing, I certify that I have read and understand the contents of this information. I am aware of the possible side effects and drug interactions and consent to treatment.  I understand that other weight loss programs are available and acknowledge no guarantees concerning results.

​

Release from Medical Liability and Malpractice Claims:

​

I agree to release BestBodyCA from all medical liability and malpractice claims related to my care. This consent covers initial and future prescriptions for this medication.

​

Non-Refundable Prescription Therapy:

​

I understand that this is a prescription therapy and is not eligible for a refund or reimbursement.

​

Acknowledgment:

​

I have read and agree to the above. My questions have been answered, and I understand the treatment and goals. I accept the potential risks associated with GLP-1 RA therapy and consent to treatment.